ACADIA PHARMACEUTICALS INC. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on neurological and rare diseases. Its core commercial products are NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE products (trofinetide) for Rett syndrome. In Q2 2026, the company launched DAYBUE STIX (a powder formulation) broadly and received a positive opinion from the European Medicines Agency (EMA) for DAYBU in the EU.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $307,959 | $264,566 | $576,021 | $508,882 |
| Net Income | $31,500 | $26,666 | $35,137 | $45,653 |
| Diluted EPS | $0.18 | $0.16 | $0.20 | $0.27 |
| Operating Cash Flow (YTD) | $134,762 (YTD 2026) vs $84,279 (YTD 2025) | |||
| Cash & Equivalents (End of Period) | $384,985 (June 30, 2026) | |||
| Investment Securities | $571,489 (June 30, 2026) | |||
| Total Assets | $1,742,900 (June 30, 2026) |
Revenue Breakdown (Q2 2026): NUPLAZID generated $183.1 million; DAYBUE products generated $124.8 million.
Margins: Gross margin (Revenue minus Cost of Product Sales) was approximately 91% for Q2 2026. Effective tax rate for Q2 2026 was 32.2%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16.4% in Q2 2026 compared to Q2 2025, driven by unit sales growth in both NUPLAZID and DAYBUE products.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to $160.3 million in Q2 2026 from $133.5 million in Q2 2025, primarily due to expanded commercial teams. R&D expenses increased slightly to $81.6 million, driven by remlifanserin and ACP-211 development.
- Liquidity: Cash and cash equivalents increased significantly from $177.7 million at year-end 2025 to $385.0 million at June 30, 2026, supported by strong operating cash flows.
- Profitability: While Q2 net income increased year-over-year, YTD net income decreased from $45.7 million in 2025 to $35.1 million in 2026, largely due to higher operating expenses and tax impacts.
Outlook, Risks, and Contingencies
- Regulatory Milestones: The EMA adopted a positive opinion for DAYBU in June 2026. The FDA granted Fast Track designation for remlifanserin (Alzheimer's disease psychosis) in July 2026. Topline results for the Phase 2 RADIANT study of remlifanserin are expected between September and October 2026.
- Legal Proceedings:
- Patent Litigation: The company won final judgments against MSN and Aurobindo regarding NUPLAZID patents in June 2025; appeals are pending. A new trial against Zydus regarding a settlement breach is scheduled for November 2026.
- Securities Litigation: A securities class action regarding prior sNDA disclosures is in pretrial stages. A derivative suit was settled in principle in July 2026, with defendants agreeing to governance reforms and a $1.5 million attorney fee award.
- Risk Factors: Key risks include the success of commercialization for DAYBUE outside the U.S., potential delays in clinical trials for remlifanserin, and the impact of geopolitical tensions and tariffs on the supply chain (specifically API sourcing).
- Capital Resources: Management expects current cash, investments, and product sales to fund operations through and beyond the next 12 months.
Investor Verification Checklist
- Verify the status of the EMA marketing authorization for DAYBU following the positive CHMP opinion.
- Monitor the Phase 2 RADIANT study results for remlifanserin expected in late 2026.
- Review the outcome of the pending appeals in the NUPLAZID patent litigation (MSN/Aurobindo) and the upcoming Zydus trial.
- Assess the impact of tariffs and trade policies on the cost of active pharmaceutical ingredients (APIs) and manufacturing.
- Track the commercial uptake of the newly launched DAYBUE STIX formulation.